Revvity, Inc. (USD) Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Revvity, Inc. (USD) Active

77 4th Avenue, Waltham, MA, US, 02451

Stock Price USD

Price Change

Last Dividend USD

B+

Latest Rating

RVTY's stock peer is ALGN (Align Technology, Inc.)

RVTY's stock peer is CRL (Charles River Laboratories International, Inc.)

RVTY's stock peer is ENSG (The Ensign Group, Inc.)

RVTY's stock peer is EXAS (Exact Sciences Corporation)

RVTY's stock peer is GH (Guardant Health, Inc.)

RVTY's stock peer is HIMS (Hims & Hers Health, Inc.)

RVTY's stock peer is ICLR (ICON Public Limited Company)

RVTY's stock peer is RDY (Dr. Reddy's Laboratories Limited)

RVTY's stock peer is SOLV (Solventum Corporation)

Healthcare Medical - Diagnostics & Research

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

80%

Dcf Rating

60%

Return On Equity

80%

Return On Assets

40%

Debt To Equity

20%

Price To Earnings

80%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-07-17	2026-08-07	0.07	0.25 %	Quarterly
2026-04-17	2026-05-08	0.07	0.30 %	Quarterly
2026-01-16	2026-02-06	0.07	0.25 %	Quarterly
2025-10-17	2025-11-07	0.07	0.30 %	Quarterly
2025-07-18	2025-08-08	0.07	0.30 %	Quarterly
2025-04-18	2025-05-09	0.07	0.30 %	Quarterly
2025-01-17	2025-02-07	0.07	0.24 %	Quarterly
2024-10-18	2024-11-08	0.07	0.23 %	Quarterly
2024-07-19	2024-08-09	0.07	0.26 %	Quarterly
2024-04-19	2024-05-10	0.07	0.28 %	Quarterly
2024-01-19	2024-02-09	0.07	0.26 %	Quarterly
2023-10-20	2023-11-10	0.07	0.28 %	Quarterly
2023-07-21	2023-08-11	0.07	0.22 %	Quarterly
2023-04-21	2023-05-12	0.07	0.21 %	Quarterly
2023-01-20	2023-02-10	0.07	0.21 %	Quarterly
2022-10-21	2022-11-11	0.07	0.22 %	Quarterly
2022-07-22	2022-08-12	0.07	0.19 %	Quarterly
2022-04-22	2022-05-13	0.07	0.18 %	Quarterly
2022-01-21	2022-02-11	0.07	0.16 %	Quarterly
2021-10-22	2021-11-12	0.07	0.16 %	Quarterly
2021-07-16	2021-08-06	0.07	0.18 %	Quarterly
2021-04-16	2021-05-07	0.07	0.21 %	Quarterly
2021-01-22	2021-02-12	0.07	0.19 %	Quarterly
2020-10-16	2020-11-06	0.07	0.23 %	Quarterly
2020-07-17	2020-08-07	0.07	0.26 %	Quarterly
2020-04-17	2020-05-08	0.07	0.34 %	Quarterly
2020-01-17	2020-02-07	0.07	0.28 %	Quarterly
2019-10-18	2019-11-08	0.07	0.34 %	Quarterly
2019-07-19	2019-08-09	0.07	0.29 %	Quarterly
2019-04-19	2019-05-10	0.07	0.30 %	Quarterly
2019-01-18	2019-02-08	0.07	0.33 %	Quarterly
2018-10-19	2018-11-09	0.07	0.32 %	Quarterly
2018-07-20	2018-08-10	0.07	0.36 %	Quarterly
2018-04-13	2018-05-10	0.07	0.38 %	Quarterly
2018-01-19	2018-02-09	0.07	0.35 %	Quarterly
2017-10-20	2017-11-10	0.07	0.39 %	Quarterly
2017-07-21	2017-08-10	0.07	0.40 %	Quarterly
2017-04-14	2017-05-10	0.07	0.49 %	Quarterly
2017-01-20	2017-02-10	0.07	0.53 %	Quarterly
		0.07	0.53 %	Quarterly
		0.07	0.50 %	Quarterly
		0.07	0.55 %	Quarterly
		0.07	0.59 %	Quarterly
		0.07	0.59 %	Quarterly
		0.07	0.53 %	Quarterly
		0.07	0.55 %	Quarterly
		0.07	0.65 %	Quarterly
		0.07	0.70 %	Quarterly
		0.07	0.61 %	Quarterly
		0.07	0.64 %	Quarterly
		0.07	0.65 %	Quarterly
		0.07	0.76 %	Quarterly
		0.07	0.84 %	Quarterly
		0.07	0.82 %	Quarterly
		0.07	0.82 %	Quarterly
		0.07	0.92 %	Quarterly
		0.07	1.12 %	Quarterly
		0.07	1.05 %	Quarterly
		0.07	1.21 %	Quarterly
		0.07	1.49 %	Quarterly
		0.07	1.06 %	Quarterly
		0.07	1.07 %	Quarterly
		0.07	1.11 %	Quarterly
		0.07	1.21 %	Quarterly
		0.07	1.48 %	Quarterly
		0.07	1.18 %	Quarterly
		0.07	1.32 %	Quarterly
		0.07	1.40 %	Quarterly
		0.07	1.60 %	Quarterly
		0.07	2.05 %	Quarterly
		0.07	2.05 %	Quarterly
		0.07	1.36 %	Quarterly
		0.07	1.01 %	Quarterly
		0.07	1.14 %	Quarterly
		0.07	1.09 %	Quarterly
		0.07	0.97 %	Quarterly
		0.07	1.03 %	Quarterly
		0.07	1.12 %	Quarterly
		0.07	1.26 %	Quarterly
		0.07	1.41 %	Quarterly
		0.07	1.34 %	Quarterly
		0.07	1.24 %	Quarterly
		0.07	1.22 %	Quarterly
		0.07	1.33 %	Quarterly
		0.07	1.31 %	Quarterly
		0.07	1.43 %	Quarterly
		0.07	1.36 %	Quarterly
		0.07	1.59 %	Quarterly
		0.07	1.69 %	Quarterly
		0.07	1.37 %	Quarterly
		0.07	1.51 %	Quarterly
		0.07	1.65 %	Quarterly
		0.07	1.94 %	Quarterly
		0.07	3.11 %	Quarterly
		0.07	3.23 %	Quarterly
		0.07	6.21 %	Quarterly
		0.07	3.23 %	Quarterly
		0.07	2.11 %	Quarterly
		0.07	0.88 %	Quarterly
		0.07	0.93 %	Quarterly
		0.07	0.93 %	Quarterly
		0.14	0.93 %	Quarterly
		0.14	0.60 %	Quarterly
		0.14	0.55 %	Quarterly
		0.14	0.78 %	Quarterly
		0.14	1.02 %	Quarterly
		0.14	1.28 %	Quarterly
		0.14	1.46 %	Quarterly
		0.14	1.61 %	Quarterly
		0.14	1.94 %	Quarterly
		0.14	2.05 %	Quarterly
		0.14	2.52 %	Quarterly
		0.14	1.97 %	Quarterly
		0.14	1.89 %	Quarterly
		0.14	2.67 %	Quarterly
		0.14	2.55 %	Quarterly
		0.14	2.60 %	Quarterly
		0.14	2.97 %	Quarterly
		0.14	2.78 %	Quarterly
		0.14	3.18 %	Quarterly
		0.14	2.82 %	Quarterly
		0.14	2.53 %	Quarterly
		0.14	3.31 %	Quarterly
		0.14	3.83 %	Quarterly
		0.14	4.06 %	Quarterly
		0.14	4.21 %	Quarterly
		0.14	4.83 %	Monthly
		0.14	4.07 %	Quarterly
		0.14	3.44 %	Quarterly
		0.14	3.60 %	Quarterly
		0.14	3.54 %	Quarterly
		0.14	2.90 %	Quarterly
		0.13	2.93 %	Quarterly
		0.13	2.67 %	Quarterly
		0.13	2.27 %	Quarterly
		0.13	2.32 %	Quarterly
		0.12	1.90 %	Quarterly
		0.12	1.67 %	Quarterly
		0.25	1.46 %	Quarterly
		0.06	1.34 %	Quarterly
		0.21	2.13 %	Quarterly
		0.21	1.98 %	Quarterly
		0.21	1.92 %	Quarterly
		0.21	2.36 %	Quarterly
		0.19	2.37 %	Quarterly
		0.19	1.92 %	Quarterly
		0.19	1.93 %	Quarterly
		0.19	2.04 %	Quarterly
		0.17	2.01 %	Quarterly
		0.17	1.88 %	Quarterly
		0.17	2.00 %	Quarterly
		0.17	2.12 %	Quarterly
		0.15	1.87 %	Quarterly
		0.15	1.77 %	Quarterly
		0.15	1.61 %	Quarterly
		0.15	1.76 %	Quarterly
		0.14	1.66 %	Quarterly
		0.14	1.61 %	Quarterly
		0.14	1.59 %	Quarterly
		0.14	1.64 %	Quarterly
		0.13	1.76 %	Quarterly
		0.13	1.47 %	Quarterly
		0.13	1.26 %	Quarterly
		0.13	1.33 %	Quarterly
		0.12	1.35 %	Quarterly
		0.12	1.12 %	Quarterly
		0.12	1.20 %	Quarterly
		0.12	1.25 %	Quarterly
		0.10	1.25 %	Quarterly
		0.10	1.35 %	Quarterly
		0.10	1.26 %	Quarterly
		0.10	1.10 %	Quarterly
		0.09	0.76 %	Quarterly
		0.09	0.50 %	Quarterly
		0.09	0.29 %	Quarterly

Recent News

Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. As scientific organizations generate increasing volumes of data acr.

2026-06-22 08:00:00

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company's FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla.

2026-05-13 08:00:00

Revvity Announces Financial Results for the First Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the quarter was $711 million, as compared to $665 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $76 million, as compared to $72 million for the same perio.

2026-05-05 06:00:00

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from dis.

2026-04-30 16:05:00

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 9:20 a.m. PT - Steve Willoughby, senior vice president, investor relations, ESG, risk Goldman Sachs 47th Annual Global Healthcare Conference Tuesday, June 9, 2026 8:40 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic pr.

2026-04-16 08:00:00

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the.

2026-04-10 08:00:00

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining.

2026-04-09 08:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions